AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10839763 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 600 mg orally once a week for 1 year
Number of subjects: 0
Study 10839763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8604669 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-modified dairy products
Number of subjects: 33
Study 8604669 — intervention group
Group type: COMPARATOR
Intervention: Conventional dairy products
Number of subjects: 33
Study 1859658 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 60
Study 1859658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2860043 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids or a combination with prednisolone and sulfasalazine
Number of subjects: 130
Study 2860043 — intervention group
Group type: COMPARATOR
Intervention: Placebo or sulfasalazine alone
Number of subjects: 130
Study 31918692 — intervention group
Group type: EXPERIMENTAL
Intervention: Written materials
Number of subjects: 98
Study 31918692 — intervention group
Group type: EXPERIMENTAL
Intervention: Video materials
Number of subjects: 98
Study 31918692 — intervention group
Group type: COMPARATOR
Intervention: Control group (no materials)
Number of subjects: 98
Study 29898870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine regimen (intramuscular injection of ALVAC-HIV vector [vCP2438] at 0, 1, 3, 6, and 12 months plus bivalent subtype C gp120 and MF59 adjuvant at 3, 6, and 12 months)
Number of subjects: 252
Study 29898870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine regimen
Number of subjects: 252
Study 29898870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 26561619 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐MTHF
Number of subjects: 136
Study 26561619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 26561619 — intervention group
Group type: COMPARATOR
Intervention: FO+5‐MTHF
Number of subjects: 136
Study 26561619 — intervention group
Group type: EXPERIMENTAL
Intervention: FO
Number of subjects: 136
Study 25193718 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol electronic screening and brief intervention (AUDIT-C)
Number of subjects: 3206
Study 23660331 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-monthly monitoring
Number of subjects: 163
Study 21476204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bletilla striata particles
Number of subjects: 59
Study 21476204 — intervention group
Group type: COMPARATOR
Intervention: Gelfoam particles
Number of subjects: 59
Study 21476204 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study 17698218 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban infusion and sirolimus-eluting stents (SES)
Number of subjects: 175
Study 17698218 — intervention group
Group type: COMPARATOR
Intervention: abciximab and bare metal stent (BMS)
Number of subjects: 175
Study 17698218 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban infusion and SES
Number of subjects: 175
Study 17698218 — intervention group
Group type: COMPARATOR
Intervention: abciximab and BMS
Number of subjects: 175
Study 16538150 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scoring system for CF lung disease
Number of subjects: 16
Study 14510794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 14
Study 14510794 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 14
Study 14510794 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 14
Study 11015240 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized racemic epinephrine
Number of subjects: 120
Study 11015240 — intervention group
Group type: COMPARATOR
Intervention: Nebulized salbutamol
Number of subjects: 120
Study 8630674 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive risk factor modification program (nonpharmacological intervention)
Number of subjects: 164
Study 8630674 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 164
Study 1451242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (1.5 M units) administered over 30 minutes
Number of subjects: 122
Study 1451242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 6487497 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100-200 mg daily)
Number of subjects: 17
Study 6487497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31661077 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose feedback (4 weeks) followed by glucose and physical activity feedback (2 weeks)
Number of subjects: 45
Study 31661077 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity feedback (4 weeks) followed by biobehavioral feedback (2 weeks)
Number of subjects: 45
Study 31661077 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobehavioral feedback (6 weeks)
Number of subjects: 45
Study 31661077 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit usage
Number of subjects: 45
Study 29150421 — intervention group
Group type: EXPERIMENTAL
Intervention: Rd continuous
Number of subjects: 1623
Study 29150421 — intervention group
Group type: COMPARATOR
Intervention: Rd18
Number of subjects: 1623
Study 29150421 — intervention group
Group type: COMPARATOR
Intervention: MPT
Number of subjects: 1623
Study 25874687 — intervention group
Group type: EXPERIMENTAL
Intervention: TissuGlu® flap fixation
Number of subjects: 205
Study 25874687 — intervention group
Group type: COMPARATOR
Intervention: Control (mastectomy only)
Number of subjects: 205
Study 24666195 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendly touch on the back during a delay-of-gratification task
Number of subjects: 40
Study 24666195 — intervention group
Group type: COMPARATOR
Intervention: No touch
Number of subjects: 40
Study 22527648 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated interventional treatment (average 10 times, approximately 107 single injections during each treatment cycle)
Number of subjects: 38
Study 20855664 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1734
Study 20855664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1734
Study 20855664 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline GDF-15 levels (per 100 ng/L)
Number of subjects: 1734
Study 18030865 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual medication schedule with brief counseling
Number of subjects: 147
Study 18030865 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 147
Study 15743327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 22
Study 15743327 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 22
Study 11898017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitest regimen of 5 sacroiliac pain provocation tests
Number of subjects: 78
Study 10594409 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 119
Study 10594409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 7588454 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate (FBM) monotherapy
Number of subjects: 40
Study 7588454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2167330 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytohemagglutinin-stimulated interleukin-2 production on day 5 after rhinovirus inoculation
Number of subjects: 0
Study 2167330 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytohemagglutinin-stimulated interferon-gamma production on day 5 after rhinovirus inoculation
Number of subjects: 0
Study 2167330 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural killer cell-mediated cytotoxicity on day 5 after rhinovirus challenge
Number of subjects: 0
Study 2167330 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific antigen-stimulated blastogenesis on day 21 after rhinovirus challenge
Number of subjects: 0
Study 6985776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine prophylaxis
Number of subjects: 0
Study 31654469 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational leaflet on safe sleeping practices
Number of subjects: 189
Study 31654469 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 189
Study 30159720 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially absorbable mesh
Number of subjects: 163
Study 30159720 — intervention group
Group type: COMPARATOR
Intervention: Native tissue repair
Number of subjects: 163
Study 28838862 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg per day)
Number of subjects: 302
Study 28838862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 25452452 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 0.3 mg/kg
Number of subjects: 168
Study 25452452 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 2 mg/kg
Number of subjects: 168
Study 25452452 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 mg/kg
Number of subjects: 168
Study 24095246 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone
Number of subjects: 20
Study 24095246 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 22303711 — intervention group
Group type: COMPARATOR
Intervention: Chronic HBV carriers (GPS and GDS)
Number of subjects: 40
Study 22303711 — intervention group
Group type: COMPARATOR
Intervention: Chronic HBV patients (GPS and GDS)
Number of subjects: 40
Study 22303711 — intervention group
Group type: COMPARATOR
Intervention: GPS group
Number of subjects: 40
Study 22303711 — intervention group
Group type: COMPARATOR
Intervention: HBV patients group
Number of subjects: 40
Study 19119079 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of need access to specialist care via the nurse specialist
Number of subjects: 237
Study 19119079 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital based 6‐monthly clinical review
Number of subjects: 237
Study 19119079 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of need access
Number of subjects: 237
Study 17330628 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpand chest drain
Number of subjects: 67
Study 17330628 — intervention group
Group type: COMPARATOR
Intervention: Standard underwater drain
Number of subjects: 67
Study 14587108 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis during laparoscopic cholecystectomy
Number of subjects: 0
Study 14587108 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (control group)
Number of subjects: 0
Study 10877008 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent paracetamol tablets (2 x 500 mg Pinex Brusetablett, Alpharma AS)
Number of subjects: 20
Study 10877008 — intervention group
Group type: COMPARATOR
Intervention: Ordinary paracetamol tablets (2 x 500 mg Panodil tablets, SmithKline Beecham)
Number of subjects: 20
Study 10877008 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent paracetamol tablets
Number of subjects: 20
Study 10877008 — intervention group
Group type: COMPARATOR
Intervention: Ordinary paracetamol tablets
Number of subjects: 20
Study 9408153 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-containing chemotherapy with involved field radiotherapy (n = 58)
Number of subjects: 76
Study 9408153 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin-containing chemotherapy without involved field radiotherapy (n = 18)
Number of subjects: 76
Study 8458821 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin mixture (daily doses of 592 mg of alpha‐tocopherol equivalents, 1,000 mg of ascorbic acid, and 30 mg of beta‐carotene)
Number of subjects: 20
Study 8458821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3728269 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine treatment
Number of subjects: 30
Study 3728269 — intervention group
Group type: COMPARATOR
Intervention: Holter criteria I
Number of subjects: 30
Study 3728269 — intervention group
Group type: COMPARATOR
Intervention: Holter criteria II
Number of subjects: 30
Study 3728269 — intervention group
Group type: COMPARATOR
Intervention: Holter criteria III
Number of subjects: 30
Study 3728269 — intervention group
Group type: COMPARATOR
Intervention: PES vs Holter I
Number of subjects: 30
Study 3728269 — intervention group
Group type: COMPARATOR
Intervention: PES vs Holter II
Number of subjects: 30
Study 3728269 — intervention group
Group type: COMPARATOR
Intervention: PES vs Holter III
Number of subjects: 30
Study 29444414 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4.8 ± 0.4 mg/kg body mass)
Number of subjects: 9
Study 29444414 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (7.3 mmol of nitrate)
Number of subjects: 9
Study 29444414 — intervention group
Group type: COMPARATOR
Intervention: Caffeine placebo
Number of subjects: 9
Study 29444414 — intervention group
Group type: COMPARATOR
Intervention: Beetroot juice placebo
Number of subjects: 9
Study 27221313 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined head position during HS-WBRT using VMAT
Number of subjects: 8
Study 27221313 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined head position
Number of subjects: 8
Study 23963103 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual tract dilation with Alken metal dilators
Number of subjects: 66
Study 23963103 — intervention group
Group type: COMPARATOR
Intervention: One-stage tract dilation
Number of subjects: 66
Study 23963103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Gradual and One-stage)
Number of subjects: 66
Study 23225450 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus and bevacizumab combination (arm A)
Number of subjects: 70
Study 23225450 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (arm B)
Number of subjects: 70
Study 23225450 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alfa and bevacizumab (arm C)
Number of subjects: 70
Study 23225450 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient group
Number of subjects: 70
Study 23225450 — intervention group
Group type: EXPERIMENTAL
Intervention: Response group
Number of subjects: 70
Study 20019628 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived neighborhood safety
Number of subjects: 890
Study 20019628 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived availability of places to walk
Number of subjects: 890
Study 20019628 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to school
Number of subjects: 890
Study 20019628 — intervention group
Group type: EXPERIMENTAL
Intervention: Active destinations in neighborhood
Number of subjects: 890
Study 20019628 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller-sized blocks
Number of subjects: 890
Study 20019628 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (race)
Number of subjects: 890
Study 19029412 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 19-9 levels lower than 180
Number of subjects: 385
Study 19029412 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 19-9 levels lower than or equal to 90
Number of subjects: 385
Study 15277322 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d
Number of subjects: 153
Study 15277322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 11342423 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasburicase
Number of subjects: 52
Study 11342423 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 52
Study 9107160 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol with exercise training
Number of subjects: 23
Study 9107160 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol with exercise training
Number of subjects: 23
Study 9107160 — intervention group
Group type: COMPARATOR
Intervention: Sedentary patients treated with carvedilol
Number of subjects: 23
Study 9107160 — intervention group
Group type: COMPARATOR
Intervention: Sedentary patients treated with propranolol
Number of subjects: 23
Study 9107160 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained patients (both carvedilol and propranolol)
Number of subjects: 23
Study 8198025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice daily, starting 2 weeks before PTCA and continuing after successful PTCA until follow-up angiography at 26 +/- 2 weeks.
Number of subjects: 730
Study 8198025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice daily
Number of subjects: 730
Study 3147048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 3147048 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose theophylline (5-10 mg/l)
Number of subjects: 38
Study 3147048 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose theophylline (10-15 mg/l)
Number of subjects: 38
Study 3147048 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose theophylline (15-20 mg/l)
Number of subjects: 38
Study 3147048 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (all doses)
Number of subjects: 38
Study 30123528 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced strength lager
Number of subjects: 0
Study 30123528 — intervention group
Group type: COMPARATOR
Intervention: Regular strength lager
Number of subjects: 0
Study 27350068 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab 100 mg + Dexamethasone 20 mg/day + Bortezomib 1.3 mg/m² (Cohort 1)
Number of subjects: 16
Study 27350068 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab 300 mg + Dexamethasone 20 mg/day + Bortezomib 1.3 mg/m² (Cohort 2)
Number of subjects: 16
Study 27350068 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Tabalumab 100 mg or 300 mg + Dexamethasone + Bortezomib)
Number of subjects: 16
Study 26276751 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy bread (34 mg isoflavones/slice)
Number of subjects: 32
Study 22976766 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with imiglucerase
Number of subjects: 12
Study 22976766 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study 20685535 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing filled enamel sealant (Pro Seal)
Number of subjects: 18
Study 20685535 — intervention group
Group type: COMPARATOR
Intervention: Unfilled nonfluoride control (Transbond MIP)
Number of subjects: 18
Study 20685535 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Pro Seal vs Transbond MIP
Number of subjects: 18
Study 18346503 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH intervention
Number of subjects: 57
Study 18346503 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient hospital-based nutrition care (RC)
Number of subjects: 57
Study 17182989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 1002
Study 17182989 — intervention group
Group type: COMPARATOR
Intervention: Cefotetan
Number of subjects: 1002
Study 12800782 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP treatment
Number of subjects: 0
Study 12800782 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled treatment trials
Number of subjects: 0
Study 12800782 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 0
Study 10742349 — intervention group
Group type: EXPERIMENTAL
Intervention: Literacy promoting intervention (developmentally appropriate children's books and educational materials)
Number of subjects: 205
Study 10742349 — intervention group
Group type: EXPERIMENTAL
Intervention: Literacy promoting intervention
Number of subjects: 205
Study 10742349 — intervention group
Group type: COMPARATOR
Intervention: Control (no books or materials relevant to literacy)
Number of subjects: 205
Study 10742349 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 205
Study 8876022 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight abstinence
Number of subjects: 49
Study 8876022 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent smoking
Number of subjects: 49
Study 8876022 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 49
Study 1557507 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 8
Study 1557507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2862032 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0
Study 2862032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0
Study 2862032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined atracurium and vecuronium
Number of subjects: 0
Study 31809622 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen receptor splice variant 7 (AR‐V7) mRNA expression in hormone-sensitive prostate cancer (HSPC) and castration-resistant prostate cancer (CRPC)
Number of subjects: 19
Study 31809622 — intervention group
Group type: EXPERIMENTAL
Intervention: AR‐FL, AR‐V7, ARv567es, AR‐V3 mRNA expression
Number of subjects: 19
Study 31809622 — intervention group
Group type: EXPERIMENTAL
Intervention: AR‐V7/AR‐FL ratio after ADT
Number of subjects: 19
Study 31809622 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendocrine differentiation
Number of subjects: 19
Study 31809622 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason score
Number of subjects: 19
Study 29405668 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (10 mg in 10 mL saline)
Number of subjects: 80
Study 29405668 — intervention group
Group type: COMPARATOR
Intervention: Saline (10 mL)
Number of subjects: 80
Study 25952561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (including cognitive group sessions and individual sessions) with biweekly telephone follow-up for 3 months
Number of subjects: 120
Study 25952561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (intervention group)
Number of subjects: 120
Study 25952561 — intervention group
Group type: COMPARATOR
Intervention: General multidisciplinary MS rehabilitation (both groups)
Number of subjects: 120
Study 24337625 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK treatment plus standard treatment
Number of subjects: 132
Study 24337625 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 132